Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies

BACKGROUND: Ruxolitinib is newly approved for glucocorticoid-refractory acute graft-versus-host disease (GVHD) in patients undergoing allo-geneic hematopoietic stem-cell transplantation (allo-HSCT), and voriconazole is commonly used in allo-HSCT recipients for the prophylaxis or treatment of invasiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yingxin, Chen, Peng, Dou, Liping, Li, Fei, Li, Meng, Xu, Lingmin, Chen, Jing, Jia, Mingyu, Huang, Sai, Wang, Nan, Luan, Songhua, Yang, Jinling, Bai, Nan, Liu, Daihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964335/
https://www.ncbi.nlm.nih.gov/pubmed/35370398
http://dx.doi.org/10.2147/DDDT.S354270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964335/
https://www.ncbi.nlm.nih.gov/pubmed/35370398
http://dx.doi.org/10.2147/DDDT.S354270

Ejemplares similares